Private Placement

A novel drug that glues cancer proteins to the cellular trash system has entered human trials, offering new hope for rare diseases like Ewing sarcoma.

A new partnership aims to move AI from costly experiments to real-world value in biopharma, combining specialized agents with strategic implementation.

Meta's historic nuclear energy purchase signals a major shift in Big Tech's strategy to meet soaring AI power demands and reshape the US energy grid.

Major drill results in New Brunswick reveal a rich antimony deposit, a key step in challenging China and Russia's grip on this strategic mineral supply.

Prescryptive and Ilant Health unveil a direct-to-employer model for obesity drugs, promising transparent pricing and better clinical outcomes for employers.

NCR Voyix is launching a new AI-driven, microservices-based platform designed to help restaurants combat labor shortages and meet rising customer expectations.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

With a huge new investment, MEDIPOST is advancing its proven stem cell therapy for knee osteoarthritis into a pivotal Phase III trial in the United States.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

A new study reveals the hidden quality-of-life toll of a common virus on transplant patients, highlighting the urgent need for targeted new therapies.

The biotech firm lands a major private placement, extending its cash runway to 2028 and signaling strong investor confidence in its novel drug platform.

Amid strong investor demand, VR Resources boosts its financing and plans a share consolidation to fuel its key copper, gold, and tungsten projects in Nevada.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

Boston's Moody Aldrich Partners commits $600M to London's SCIO Capital, a major validation of specialized asset-backed lending in Europe's booming market.

The global VR leader continues its rapid Canadian growth, opening a high-tech virtual reality venue in Vaughan amid a booming market for immersive group fun.

With its radical solar car on the line, Aptera appoints a VW and BMW veteran as Chairman. Can traditional auto expertise finally launch a new era of efficiency?

With a $200M facility, BlackOpal's GemStone uses blockchain to offer institutional investors high-yield Brazilian assets without the traditional credit risk.